A recent rule will let the US Department of Health and Human Services (HHS) require drugmakers to pay back rebates on drugs that increase in price faster than inflation. The department has announced its list of the first 27 drugs to face this process, including therapeutics from pharma giants like Pfizer, Gilead, and AbbVie.
According to Zachary Brennan, “The five Pfizer drugs include older drugs like the blood thinner Fragmin (dalteparin), which first won FDA approval in 1994; Atgam, which is for allograft rejection in renal transplant patients; and the chemo Nipent (pentostatin), as well as antibacterial drugs, Bicillin L-A and Bicillin C-R.”
To read more, click here.
(Source: Endpoints News, March 15th, 2023)
